Paragon 28 Names Scott Drake to its Board of Directors

 Paragon 28 Inc. announced that Scott Drake has joined its Board of Directors. 
 
“Scott is an accomplished leader in the medical technology space, possessing both outstanding strategic vision and operational know-how,” said Albert DaCosta, co-founder, president, and CEO of Paragon 28. “Scott is a great cultural fit at Paragon 28, and we are delighted to have Scott join the Board. Scott’s value-creating leadership experiences at publicly-traded, global medical technology companies will immediately benefit Paragon 28.”
 
Drake is currently CEO and president of ViewRay, an MRI-guided radiation therapy company. Previously, Drake was CEO and president of Spectranetics Corporation until its acquisition by Royal Philips in August 2017. During his six-year tenure at Spectranetics, revenue increased from $60 million to nearly $300 million and shareholder value increased from approximately $170 million to $2.2 billion. Prior to Spectranetics, Drake served as senior vice president, Operations, at DaVita Inc., a U.S. provider of kidney care and dialysis, from 2009 to August 2011.  

Drake held several positions of increasing responsibility within various healthcare business units at Covidien plc over a period of 17 years, including president of Covidien’s $1.5 billion Respiratory and Monitoring Solutions Global Business. He also served as board chairman at AtriCure, an innovator in treatments for atrial fibrillation and left atrial appendage and as the chairperson of the AdvaMed Radiation Therapy Sector. Drake previously served on the Board of Directors for The Zayo Group Holdings Inc, which was acquired by Digital Colony and EQT for $14.3 billion, Just Right Surgical, and the Medical Device Manufacturers Association (MDMA). Drake is an Ernst & Young 2014 Entrepreneur of The Year and earned a bachelor of science in business administration from Miami University of Ohio. 
 
“I am thrilled  to join the Board of Directors at Paragon 28 in addressing the unmet and under-served needs of the foot and ankle community. Paragon has an impressive track record of growth fueled by an innovative and comprehensive suite of solutions,” said Drake. “I look forward to helping Paragon 28 achieve its growth agenda and mission of improving patient outcomes and lives.”
 
Paragon 28 is a privately held, orthopedic medical device company based in Englewood, Colo., focused exclusively on the foot and ankle.